Big Techs consider adopting stablecoins as GENIUS Act debate continues

Growing momentum for United States stablecoin regulation is reportedly pushing major tech firms like Apple, X, and Airbnb to explore digital token integration
According to a June 6 report from Fortune, at least four tech companies, including Apple, X, Airbnb and Google, are exploring stablecoins as a means to lower fees and improve cross-border payments. Each company is in a different stage of implementation, with Google perhaps the farthest ahead, having facilitated two stablecoin payments already.
Payment infrastructure companies are playing a role. For instance, Airbnb has been talking with Worldpay about using stablecoins, seeking to cut fees from credit card payment processors like Visa and Mastercard.
Social platform X has been talking with crypto companies about integrating stablecoins into its X Money app, the report says. Elon Musk has previously stated that he wants to broaden X's reach to allow users to send and receive money. The company has already pursued money transmitter licenses across the US.
A spokesperson for Google told Cointelegraph that the company is 'focused on responding to customer demand for efficient, 24/7 payments' and is 'evaluating stablecoins that allow us to provide that in a safe and sound manner.' The tech giant is also helping its customers to explore stablecoins by offering its ledger technology.
Stablecoins have become one of crypto's most popular use cases. The market capitalization for such assets has risen to $249.3 billion from $131.3 billion since January 2024, a jump of 90%.
Partnerships between stablecoin infrastructure and tech companies have been on the rise as well. Among the partnerships are Mastercard's alliance with MoonPay and Visa's deal with Bridge. In October 2024, Stripe announced its $1.1 billion acquisition of Bridge, which Fortune labeled the 'starting gun' for people in Silicon Valley to take stablecoin technology seriously.
Paxos, a crypto company known for stablecoins, has partnered with both Stripe and PayPal to provide services. For Stripe, Paxos planned to launch a new stablecoin payments platform. Paxos is also the company supporting PayPal's PYUSD stablecoin, which has a $978 million market capitalization. GENIUS Act sparks debate in US Senate
The 'Guiding and Establishing National Innovation for U.S. Stablecoins Act,' otherwise known as the GENIUS Act, is one of the developments pushing companies to explore digital assets.
The bill seeks to provide a regulatory framework for stablecoins and their issuers in the country, but has been met with debate about Big Tech's potential participation in the crypto industry.
According to The New York Times, Republican Senator Josh Hawley recently said he would vote against the bill in its current form as it would allow tech companies the ability to issue digital currencies that would compete with the dollar.
Democrats plan to add an amendment that would ban Big Tech companies from creating their own stablecoins, according to the NYT, citing a person with knowledge of the plan. The move would force tech companies operating in the US to use established stablecoin companies, including Tether and Circle.
Source: https://cointelegraph.com/news/big-tech-considers-adopting-stablecoins-as-genius-act-debate-continues

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Tatler Asia

3 days ago

• Tatler Asia

Can AI really think or only create an illusion of thinking?

This debate between experts shows bigger disagreements about how to test AI and measure machine thinking. While Apple's research suggests we should be careful about current AI abilities, critics say it's the testing methods that have their limitations, which in turn can't prove that AI systems have major limits. The debate comes down to whether these systems can really think or just pretend to think well. As AI keeps getting better quickly, creating proper ways to test it becomes more important for understanding what these technologies can and can't do reliably.

South China Morning Post

13-06-2025

• South China Morning Post

Nearly all Foxconn India iPhones shipping to US as Apple looks to bypass China tariffs

Nearly all the iPhones exported by Foxconn from India went to the United States between March and May, customs data showed, far above the 2024 average of 50 per cent and a clear sign of Apple 's efforts to bypass high US tariffs imposed on China. The numbers, being reported by Reuters for the first time, show Apple has realigned its India exports to almost exclusively serve the US market, when previously the devices were more widely distributed to countries including the Netherlands, the Czech Republic and Britain. During March-May, Foxconn exported iPhones worth US$3.2 billion from India, with an average of 97 per cent shipped to the United States, compared to a 2024 average of 50.3 per cent, according to commercially available customs data seen by Reuters. India iPhone shipments by Foxconn to the United States in May 2025 were worth nearly US$1 billion, the second-highest ever after the record US$1.3 billion worth of devices shipped in March, the data showed. Apple and Foxconn did not respond to Reuters' requests for comment. US President Donald Trump holds an iPhone after it rang while he was speaking at the White House on May 23. Photo: Reuters

Globe and Mail

13-06-2025

• Globe and Mail

NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Companies and 10+ Therapies

DelveInsight's, 'Non-Small-Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the NSCLC Treatment Landscape. Click here to read more @ NSCLC Pipeline Outlook Key Takeaways from the NSCLC Pipeline Report In June 2025, Revolution Medicines Inc. announced a study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel. This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy. In June 2025, Amgen conducted a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR). In June 2025, Allist Pharmaceuticals Inc. organized a Phase 3 clinical study to assess the efficacy and safety of adjuvant treatment with firmonertinib versus placebo in participants with Stage IB-IIIB NSCLC with uncommon EGFR mutations (exon 20 insertions, PACC and classical-like mutations) after complete surgical resection with or without adjuvant chemotherapy. In June 2025, AstraZeneca announced a Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type advanced or metastatic NSCLC. DelveInsight's NSCLC pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for NSCLC treatment. The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. Stay informed about the cutting-edge advancements in NSCLC treatments. Download for updates and be a part of the revolution in cancer care @ NSCLC Clinical Trials Assessment NSCLC Emerging Drugs Profile AMG 510: Amgen AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC. CMP 001: Cytos Biotechnology CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer. The NSCLC Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment. NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different NSCLC mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market Learn more about NSCLC Drugs opportunities in our groundbreaking NSCLC research and development projects @ NSCLC Unmet Needs NSCLC Companies GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Parenteral Intramuscular Molecule Type NSCLC Products have been categorized under various Molecule types such as Small molecules Peptides Polymer Gene Therapy Monoclonal antibodies Product Type Discover the latest advancements in NSCLC treatment by visiting our website. Stay informed about how we're transforming the future of neurology @ NSCLC Market Drivers and Barriers, and Future Perspectives Scope of the NSCLC Pipeline Report Coverage- Global NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, and Sanofi are actively involved in research and development. Additionally, innovative biotechs like IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, TYK Medicines, Inc. and others. NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, sintilimab combined with anlotinib, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab and others. NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of NSCLC Pipeline on our website @ NSCLC Emerging Drugs and Companies Table of Contents Introduction Executive Summary Non-Small-Cell Lung cancer (NSCLC): Overview Pipeline Therapeutics Therapeutic Assessment Non-Small-Cell Lung cancer (NSCLC) – DelveInsight's Analytical Perspective In-depth Commercial Assessment Late Stage Products (Pre Registration) AMG 510: Amgen Drug profiles in the detailed report….. Mid Stage Products (Phase II) Drug Name: Company Name Drug profiles in the detailed report….. Early Stage Products (Phase I) CMP 001: Cytos Biotechnology Inactive Products Non-Small-Cell Lung cancer (NSCLC) Key Companies Non-Small-Cell Lung cancer (NSCLC) Key Products Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion Non-Small-Cell Lung cancer (NSCLC) Analyst Views Non-Small-Cell Lung cancer (NSCLC) Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: